S&P 500   4,565.99 (+0.24%)
DOW   35,555.10 (+0.39%)
QQQ   391.03 (+0.22%)
AAPL   189.45 (-0.50%)
MSFT   378.83 (-1.01%)
META   333.24 (-1.70%)
GOOGL   135.23 (-1.44%)
AMZN   146.54 (-0.33%)
TSLA   246.72 (+0.00%)
NVDA   481.31 (+0.65%)
NIO   7.22 (+0.14%)
BABA   74.91 (-2.38%)
AMD   124.51 (+2.05%)
T   16.27 (+0.56%)
F   10.66 (+2.80%)
MU   76.86 (+0.97%)
CGC   0.56 (+3.70%)
GE   119.25 (+0.34%)
DIS   92.96 (+0.50%)
AMC   7.18 (+7.16%)
PFE   30.08 (+1.31%)
PYPL   58.38 (-0.15%)
XOM   103.54 (-0.35%)
S&P 500   4,565.99 (+0.24%)
DOW   35,555.10 (+0.39%)
QQQ   391.03 (+0.22%)
AAPL   189.45 (-0.50%)
MSFT   378.83 (-1.01%)
META   333.24 (-1.70%)
GOOGL   135.23 (-1.44%)
AMZN   146.54 (-0.33%)
TSLA   246.72 (+0.00%)
NVDA   481.31 (+0.65%)
NIO   7.22 (+0.14%)
BABA   74.91 (-2.38%)
AMD   124.51 (+2.05%)
T   16.27 (+0.56%)
F   10.66 (+2.80%)
MU   76.86 (+0.97%)
CGC   0.56 (+3.70%)
GE   119.25 (+0.34%)
DIS   92.96 (+0.50%)
AMC   7.18 (+7.16%)
PFE   30.08 (+1.31%)
PYPL   58.38 (-0.15%)
XOM   103.54 (-0.35%)
S&P 500   4,565.99 (+0.24%)
DOW   35,555.10 (+0.39%)
QQQ   391.03 (+0.22%)
AAPL   189.45 (-0.50%)
MSFT   378.83 (-1.01%)
META   333.24 (-1.70%)
GOOGL   135.23 (-1.44%)
AMZN   146.54 (-0.33%)
TSLA   246.72 (+0.00%)
NVDA   481.31 (+0.65%)
NIO   7.22 (+0.14%)
BABA   74.91 (-2.38%)
AMD   124.51 (+2.05%)
T   16.27 (+0.56%)
F   10.66 (+2.80%)
MU   76.86 (+0.97%)
CGC   0.56 (+3.70%)
GE   119.25 (+0.34%)
DIS   92.96 (+0.50%)
AMC   7.18 (+7.16%)
PFE   30.08 (+1.31%)
PYPL   58.38 (-0.15%)
XOM   103.54 (-0.35%)
S&P 500   4,565.99 (+0.24%)
DOW   35,555.10 (+0.39%)
QQQ   391.03 (+0.22%)
AAPL   189.45 (-0.50%)
MSFT   378.83 (-1.01%)
META   333.24 (-1.70%)
GOOGL   135.23 (-1.44%)
AMZN   146.54 (-0.33%)
TSLA   246.72 (+0.00%)
NVDA   481.31 (+0.65%)
NIO   7.22 (+0.14%)
BABA   74.91 (-2.38%)
AMD   124.51 (+2.05%)
T   16.27 (+0.56%)
F   10.66 (+2.80%)
MU   76.86 (+0.97%)
CGC   0.56 (+3.70%)
GE   119.25 (+0.34%)
DIS   92.96 (+0.50%)
AMC   7.18 (+7.16%)
PFE   30.08 (+1.31%)
PYPL   58.38 (-0.15%)
XOM   103.54 (-0.35%)

Treace Medical Concepts Stock Price, News & Analysis (NASDAQ:TMCI)

$9.08
+0.40 (+4.61%)
(As of 01:39 PM ET)
Compare
Today's Range
$8.80
$9.37
50-Day Range
$6.03
$13.89
52-Week Range
$5.27
$27.97
Volume
265,862 shs
Average Volume
547,950 shs
Market Capitalization
$560.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.92

Treace Medical Concepts MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
104.5% Upside
$18.92 Price Target
Short Interest
Bearish
8.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Treace Medical Concepts in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

321st out of 949 stocks

Surgical & Medical Instruments Industry

45th out of 96 stocks


TMCI stock logo

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Stock Price History

TMCI Stock News Headlines

Treace Medical Concepts (NASDAQ:TMCI) Sees Large Volume Increase
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Treace Medical Concepts Inc TMCI
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Q3 2023 Treace Medical Concepts Inc Earnings Call
Treace Medical Concepts Disappoints On Q3 Results, Lowers FY23 Guidance
Treace to Present at Stifel 2023 Healthcare Conference
TMCI Treace Medical Concepts, Inc.
Treace to Report Third Quarter 2023 Financial Results
The Latest Analyst Ratings for Treace Medical Concepts
Treace Medical Concepts (NASDAQ: TMCI)
See More Headlines
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMCI
Fax
N/A
Employees
423
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.92
High Stock Price Target
$27.50
Low Stock Price Target
$11.00
Potential Upside/Downside
+117.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-42,810,000.00
Pretax Margin
-27.28%

Debt

Sales & Book Value

Annual Sales
$141.84 million
Book Value
$1.09 per share

Miscellaneous

Free Float
43,981,000
Market Cap
$535.38 million
Optionable
Not Optionable
Beta
0.17
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 51)
    CEO, Founder & Director
    Comp: $1.04M
  • Mr. Mark L. Hair CPA (Age 53)
    Chief Financial Officer
    Comp: $628.6k
  • Mr. Aaron J. Berutti (Age 44)
    Senior Vice President of Sales
    Comp: $519.41k
  • Mr. Terry W. Lubben (Age 58)
    Senior Vice President of Operations
  • Ms. Julie D. Dewey (Age 62)
    Chief Communications & Investor Relations Officer
  • Mr. Scot M. Elder (Age 48)
    Chief Legal & Compliance Officer and Corporate Secretary
  • Mr. Nathan Minnich
    Senior Vice President of Marketing
  • Mr. Daniel E. Owens (Age 51)
    Chief Human Resources Officer
  • Mr. Jaime A. Frias (Age 61)
    Chief Business Development Officer
    Comp: $271.04k
  • Dr. Sean F. Scanlan Ph.D. (Age 40)
    Chief Innovation Officer














TMCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price target for 2024?

6 Wall Street analysts have issued 12 month price objectives for Treace Medical Concepts' shares. Their TMCI share price targets range from $11.00 to $27.50. On average, they predict the company's stock price to reach $18.92 in the next year. This suggests a possible upside of 108.1% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2023?

Treace Medical Concepts' stock was trading at $22.99 at the beginning of 2023. Since then, TMCI stock has decreased by 60.5% and is now trading at $9.09.
View the best growth stocks for 2023 here
.

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our TMCI earnings forecast
.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) posted its earnings results on Thursday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The business had revenue of $40.76 million for the quarter, compared to analyst estimates of $42.08 million. Treace Medical Concepts had a negative net margin of 27.28% and a negative trailing twelve-month return on equity of 37.68%.

When did Treace Medical Concepts IPO?

(TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (2.90%), Emerald Advisers LLC (2.39%), TimesSquare Capital Management LLC (2.32%), Emerald Mutual Fund Advisers Trust (1.94%), Loomis Sayles & Co. L P (1.83%) and Kornitzer Capital Management Inc. KS (1.10%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends
.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TMCI) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -